Superworth

Alnylam Pharmaceuticals EPS ALNY

Diluted earnings per share by quarter and over the last twelve months, from 2009.

Last 12 months, to Jun 30, 2026
$5.93
Latest quarter, Q2 FY26
$1.21
Fiscal year 2025
$2.52

Alnylam Pharmaceuticals' earnings per share was $5.93 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $1.21.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$2.52n/a
FY2024−$2.17n/a
FY2023−$3.56n/a
FY2022−$9.29n/a
FY2021−$7.20n/a
FY2020−$7.45n/a
FY2019−$8.14n/a
FY2018−$7.56n/a
FY2017−$5.41n/a
FY2016−$4.79n/a
FY2015−$3.45n/a
FY2014−$5.14n/a
FY2013−$1.43n/a
FY2012−$2.08n/a
FY2011−$1.36n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$1.21n/a$5.93
Q1 FY26$1.51n/a$4.17
Q4 FY25$1.37n/a$2.52
Q3 FY25$1.84n/a$0.50
Q2 FY25−$0.55n/a−$2.21
Q1 FY25−$0.14n/a−$1.79
Q4 FY24−$0.65n/a−$2.17
Q3 FY24−$0.87−176%−$2.62
Q2 FY24−$0.13n/a−$0.60
Q1 FY24−$0.52n/a−$2.68
Q4 FY23−$1.10n/a−$3.56
Q3 FY23$1.15n/a−$4.14

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ALNYAlnylam Pharmaceuticals$5.93
UTHRUnited Therapeutics$27.95+9% a year
INCYIncyte$7.85+78% a year
ONCBeOne Medicines$0.43
EXELExelixis$3.18+53% a year
NBIXNeurocrine Biosciences$6.82+102% a year
HALOHalozyme Therapeutics$3.35−23% a year
TECHBIO-TECHNE$1.15+150% a year
REGNRegeneron Pharmaceuticals$40.44+2% a year
RGENRepligen$0.73
KRYSKrystal Biotech$7.98+62% a year
Peer median$5.08

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.